Ma’an Muhsin, MD

Ma’an Muhsin, MD

President & Chief Medical Officer, Kriya Oncology

  • Bio
    Ma’an Muhsin is the President and Chief Medical Officer for Kriya Oncology, the company’s oncology therapeutic area. He previously served as Chief Medical Officer at Medicenna Therapeutics where he designed and executed clinical trials of the company’s solid tumor programs. Prior to joining Medicenna, he served as Medical Lead, Oncology Clinical Development for Nektar Therapeutics where he oversaw the progression of the PIVOT-12 and REVEAL clinical studies for metastatic melanoma and advanced and local solid tumors, respectively. Dr. Muhsin has held roles of increasing responsibility at HUYA Bioscience International where he served as the Senior Vice President, Oncology Clinical Development, and at Halozyme Therapeutics where he served as Senior Medical Director, Oncology Clinical Development. He also worked in the U.S. Army Combat Support Hospitals (CSH) and held other positions within the Medical Brigade and the Medical Command under the United States Department of Defense (DoD). Dr. Muhsin completed his medical education at the Baghdad University School of Medicine and completed postgraduate education in oncology drug development at Tufts University Center for the Study of Drug Development (CSDD).